BW-1003C87

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameBW-1003C87
Drug Alias NameBW-1003C87
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel alpha subunit blockersGlutamate [NMDA] receptor antagonists
TargetsSodium channel alpha subunitGlutamate [NMDA] receptor
Therapy Area/IndicationsEpilepsyStroke
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsEpilepsyStroke

Other Information

ATC CodeN/A
Related LinksN/A